Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies

Main Article Content

Alan Menter
Erin Boh
George Lewitt
Abby Jacobson

Keywords

brodalumab, psoriasis, post hoc phase 3 study analysis

Abstract

N/A

References

1. Siliq [package insert]. Bausch Health US, LLC; 2017. 2. Lebwohl et al. N Engl J Med. 2015;373:1318-1328.

Most read articles by the same author(s)

1 2 3 > >>